Visão geral da empresa
A biotechnology enterprise operating within the healthcare sector, Tarsus Pharmaceuticals, Inc. focuses on the commercial stage development and commercialization of therapeutic candidates specifically for eye care applications in the United States. The company's core product offering includes XDEMVY, a lotilaner ophthalmic solution designed for the treatment of demodex blepharitis. As a publicly traded entity, the company currently maintains a market capitalization of $3.06 billion, supported by annual revenue of $451.36 million and a workforce comprising 370 employees. These valuation and revenue metrics indicate that the company possesses a substantial market presence within the specialized ophthalmology niche, positioning it as a significant player despite being in a growth phase of development. The scale of operations, reflected in the multi-billion dollar market cap, suggests that the market assigns high value to the company's pipeline potential and the commercial viability of its flagship eye care therapies.
Saúde financeira
The company reported revenue of $451.36 million over the trailing twelve months, yet it recorded a net income of -$66.418 million and an EBITDA of -$69.153 million, revealing a significant gap between top-line sales and profitability. This disparity highlights a cost structure where operating expenses, likely driven by research and development or commercialization costs, substantially exceed the gross profit generated from sales. Free cash flow stands at -$164.000, indicating that the company is currently consuming cash rather than generating it from operations, which impacts its immediate financial flexibility and reliance on existing reserves. Despite the negative earnings, the company holds a robust cash balance of $417.27 million against total debt of $83.04 million, suggesting a relatively conservative balance sheet regarding leverage. The debt-to-equity ratio is recorded at 24.18, which, while numerically high, must be interpreted in the context of the substantial cash holdings that effectively net out much of the debt burden. Liquidity is further supported by a current ratio of 3.85, demonstrating that the company possesses more than three times the current assets necessary to cover its short-term liabilities. However, the return on equity is -23.4% and the return on assets is -9.4%, metrics that reveal that management has not yet achieved positive returns on capital deployed, a common characteristic for biotechnology firms still in the expansion or commercialization phase.
Avaliação de valorização
Valuation metrics for Tarsus Pharmaceuticals present a complex picture, with a trailing twelve-month P/E ratio listed as N/A due to the lack of positive net income, while the forward P/E is estimated at 24.89. The divergence between a non-existent trailing P/E and a specific forward P/E implies that the market is pricing in expected future earnings growth that will eventually turn the current losses into profits. The price-to-book ratio is 8.91, indicating that the market values the company at nearly nine times its net asset value, reflecting a significant premium assigned to the intangible value of its drug pipeline. Alternative valuation measures include a price-to-sales ratio of 6.78 and an EV/EBITDA of -39.41, which suggests that traditional earnings-based valuations are not applicable and that investors are relying heavily on revenue multiples and potential. The stock has traded within a 52-week range bounded by a high of $85.25 and a low of $38.51, and without the specific current share price provided in the facts, the exact percentage distance from these bounds cannot be calculated, though the wide range underscores the volatility typical of biotech equities. The beta of 0.63 indicates that the stock's price volatility is lower than the broader market, moving less aggressively than the S&P 500 during periods of general market fluctuation.
Growth & Income
Revenue growth year-over-year is impressive at 128.4%, whereas earnings growth is N/A, illustrating that top-line expansion is occurring at a pace that currently outstrips the ability to generate net income. Since earnings are not yet positive, the concept of earnings growing faster or slower than revenue is moot in a traditional sense, as the negative earnings are a function of the heavy investment required to reach profitability rather than an operational inefficiency. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, meaning the 0.0% payout ratio is inherently sustainable given the absence of dividends but also signifies that all available cash is retained for reinvestment. The overall growth and income profile is defined by aggressive revenue expansion coupled with a complete reinvestment strategy, foregoing dividend income to fuel the development of therapeutic candidates for the eye care market.